IOVA Logo

Iovance Biotherapeutics, Inc. (IOVA) 

NASDAQ
Market Cap
$3.67B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
6 of 776
Rank in Industry
6 of 433

Largest Insider Buys in Sector

IOVA Stock Price History Chart

IOVA Stock Performance

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or …

Insider Activity of Iovance Biotherapeutics, Inc.

Over the last 12 months, insiders at Iovance Biotherapeutics, Inc. have bought $48.33M and sold $0 worth of Iovance Biotherapeutics, Inc. stock.

On average, over the past 5 years, insiders at Iovance Biotherapeutics, Inc. have bought $47.89M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Rothbaum Wayne P. (director) — $45.75M. MCPEAK MERRILL A (director) — $4.58M. Dukes Iain D. (director) — $292,800.

The last purchase of 5,000,000 shares for transaction amount of $45.75M was made by Rothbaum Wayne P. (director) on 2024‑02‑20.

List of Insider Buy and Sell Transactions, Iovance Biotherapeutics, Inc.

2024-02-20Purchasedirector
5M
1.4985%
$9.15$45.75M-12.01%
2024-02-20Purchasedirector
250,000
0.0749%
$9.15$2.29M-12.01%
2024-02-20Purchasedirector
32,000
0.0096%
$9.15$292,800-12.01%
2023-09-18Purchasedirector
10,000
0.0038%
$5.56$55,600+43.84%
2023-09-15Purchasedirector
5M
2.0294%
$5.30$26.5M+60.34%
2022-12-21Purchasedirector
10,000
0.0062%
$6.15$61,500+5.62%
2022-12-02Purchasedirector
10M
5.7676%
$6.50$65M-6.58%
2022-11-29Purchasedirector
10,000
0.0062%
$6.31$63,100+4.32%
2022-11-28Purchasedirector
10,000
0.0063%
$6.18$61,800+7.65%
2022-11-28PurchaseInterim CEO & General Counsel
1,000
0.0006%
$5.98$5,980+7.65%
2022-11-23Purchasedirector
10,000
0.006%
$6.10$61,000+3.05%
2022-06-01PurchaseInterim CEO & General Counsel
1,000
0.0006%
$6.44$6,440+22.88%
2022-05-31Purchase
500,000
0.3188%
$6.77$3.38M+15.11%
2022-05-31Purchase
2,187
0.0014%
$6.79$14,850+15.11%
2022-05-31Purchase
10,000
0.0064%
$6.84$68,400+15.11%
2022-05-31Purchase
7,500
0.0048%
$6.75$50,588+15.11%
2018-12-18Purchasedirector
24,000
0.0202%
$8.65$207,593+114.64%
2018-12-13Purchasedirector
20,000
0.0082%
$4.81$96,273+84.26%
2018-12-06Purchasedirector
600,000
0.4993%
$9.86$5.92M+82.46%
2018-12-04Purchasedirector
1.84M
1.6109%
$10.31$18.99M+82.22%

Insider Historical Profitability

37.45%
Rothbaum Wayne P.director
28067333
9.2475%
$12.0960+43.3%
MCPEAK MERRILL Adirector
320150
0.1055%
$12.0990+33.49%
Dukes Iain D.director
54000
0.0178%
$12.0930+58.85%
BRISTOL INVESTMENT FUND LTD10 percent owner
10023628
3.3025%
$12.0910
Singh ManishPresident & CEO
1938500
0.6387%
$12.0910+84%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$369.24M8.924.92M+9.22%+$31.16M0.01
MHR Fund Management$355.64M8.5824M+20%+$59.28M34.36
BlackRock$295.36M7.1219.93M+4.5%+$12.71M0.01
Perceptive Advisors$285.63M6.8919.27M+60.88%+$108.09M0.18
Avoro Capital Advisors Llc$173.39M4.1811.7M+74.63%+$74.1M2.08
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.